FibroBiologics, Inc. Common Stock
0.5M
$4.86M
-10.78
$-0.42
No price alerts set. Add an alert to get notified!
-10.78
32.65
$-0.42
-302.89%
0.00%
0.00%
Compare TSM with similar companies in the sector
| Company | Price | Change % | P/E | Market Cap | D/E |
|---|---|---|---|---|---|
|
ADTX
Aditxt, Inc.
|
$0.78 | -3.64% | 0.00 | $2,099 | -0.71 |
|
AIMD
Ainos, Inc.
|
$1.35 | -2.88% | -0.41 | $6.48M | 1.10 |
|
APLM
Apollomics, Inc.
|
$16.71 | -3.19% | -0.59 | $18.44M | -0.17 |
|
ATHA
Athira Pharma, Inc.
|
$6.75 | -6.12% | -0.99 | $26.62M | 0.03 |
|
CTXR
Citius Pharmaceuticals, Inc.
|
$0.68 | -5.42% | -0.41 | $7.60M | 0.02 |
|
DARE
Daré Bioscience, Inc.
|
$1.84 | 18.71% | -1.99 | $17.52M | 934.35 |
|
HOTH
Hoth Therapeutics, Inc.
|
$0.77 | -4.46% | -0.96 | $10.21M | 0.00 |
|
ICU
SeaStar Medical Holding Corporation
|
$3.56 | 29.93% | -6.07 | $9.94M | 0.05 |
|
LPTX
Leap Therapeutics, Inc.
|
$0.66 | -3.91% | -2.27 | $27.18M | 0.00 |
|
MBRX
Moleculin Biotech, Inc.
|
$2.23 | -8.61% | -1.10 | $2.70M | 0.02 |
* Peer stocks are selected based on market capitalization and sector
$3.89
$0.22
$0.00
0.00%
FibroBiologics, Inc., a clinical-stage cell therapy company, develops and commercializes fibroblast-based therapies in the United States. It is developing CybroCell, for the treatment of degenerative disc disease; CYMS101 to treat multiple sclerosis; and CYWC628 for wound healing. The company is also on the early-stage research of CYTER915, which is designed to regenerate or reinvigorate production of the thymus and/or spleen; CYPS317, for the treatment of psoriasis; and TCB190 to treat certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.
